Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefotaxime + sulbactam is a combination antibiotic used to treat a wide range of serious bacterial infections. Cefotaxime is a third-generation cephalosporin antibiotic that works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Sulbactam is a beta-lactamase inhibitor that protects cefotaxime from degradation by beta-lactamase enzymes produced by resistant bacteria, thereby extending the spectrum of activity of cefotaxime. This combination is effective against both gram-positive and gram-negative bacteria, including some beta-lactamase-producing strains. It is commonly administered via intravenous or intramuscular injection for conditions such as respiratory tract infections (including pneumonia), urinary tract infections, skin and soft tissue infections, bone and joint infections, intra-abdominal infections (such as peritonitis), gynecological infections (including pelvic inflammatory disease), septicemia, meningitis, and for surgical prophylaxis[2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefotaxime + sulbactam.